Jeff la Rosa

Vice President - Equity Research, Biopharma at Leerink Partners

Jeff La Rosa has a diverse work experience spanning different industries. Jeff began their career as a Research Technician in Oncology at the Children's Hospital of Pittsburgh from July 2012 to July 2013. Jeff then pursued their studies and worked as a Student Consultant at The Heller School for Social Policy and Management at Brandeis University from January 2015 to May 2015. After completing their studies, they joined Wedbush Securities as a Senior Equity Research Associate focused on Biotechnology from June 2017 to September 2020. Jeff's most recent role is with SVB Securities, where they started as an Equity Research Associate - Biopharma in September 2020 and has been promoted to Vice President - Equity Research, Biopharma starting in February 2023.

Jeff La Rosa's education history is as follows:

From 2008 to 2012, they attended the University of Pittsburgh and obtained a Bachelor of Arts degree in History.

In 2013, they enrolled in Tufts University School of Medicine and completed a Master's degree in Biomedical Sciences in 2015.

During the same period, from 2014 to 2015, they also pursued a Master of Business Administration (M.B.A.) with a focus on Health/Health Care Administration/Management at The Heller School for Social Policy and Management at Brandeis University.

In 2015, they furthered their education by attending Albany Medical College, where they obtained a Doctor of Medicine (M.D.) degree in Medicine in 2016.

Jeff La Rosa also holds several additional certifications. In 2017, they obtained an Online Professional Certificate in Capital Markets from the New York Institute of Finance. Jeff also has certifications in Series 7, Series 86, and Series 87 from FINRA (Financial Industry Regulatory Authority), although the specific dates of when they obtained these certifications are not provided.

Links

Previous companies

Wedbush Securities logo

Timeline

  • Vice President - Equity Research, Biopharma

    February, 2023 - present

  • Equity Research Associate Biopharma

    September, 2020